Background: Acupuncture has traditionally been used in the treatment of inflammatory bowel disease in China and is increasingly being applied in Western countries. The purpose of this study was to investigate the efficacy of acupuncture in the treatment of active Crohn’s disease (CD). Methods: A prospective, randomized, controlled, single-blind clinical trial was carried out to analyze the change in the CD activity index (CDAI) after treatment as a main outcome measure, and the changes in quality of life and general well-being, serum markers of inflammation (α1-acid glycoprotein, C-reactive protein) as secondary outcome measures. 51 patients with mild to moderately active CD were treated in a single center for complementary medicine by three trained acupuncturists and randomly assigned to receive either traditional acupuncture (TCM group, n = 27) or control treatment at non-acupuncture points (control group, n = 24). Patients were treated in 10 sessions over a period of 4 weeks and followed up for 12 weeks. Results: In the TCM group the CDAI decreased from 250 ± 51 to 163 ± 56 points as compared with a mean decrease from 220 ± 42 to 181 ± 46 points in the control group (TCM vs. control group: p = 0.003). In both groups these changes were associated with improvements in general well-being and quality of life. With regard to general well-being, traditional acupuncture was superior to control treatment (p = 0.045). α1-acid glycoprotein concentration fell significantly only in the TCM group (p = 0.046). Conclusions: Apart from a marked placebo effect, traditional acupuncture offers an additional therapeutic benefit in patients with mild to moderately active CD.

Keywords:
Acupuncture, Complementary medicine, Crohn’s disease, Activity index, Crohn’s disease, Inflammatory bowel disease, Chinese medicine, traditional
1.
Eisenberg DM, Kessler RC, Foster C, et al: Unconventional medicine in the United States. N Engl J Med 1993;328:246–252.
2.
Greenfell A, Patel N, Robinson N: Complementary therapy: General practitioners’ referral and patients’ use in an urban multi-ethnic area. Complement Ther Med 1998;6:127–132.
3.
Rawsthorne P, Shanahan F, Cronin NC, et al: An International survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol 1999;94:1298–1303.
4.
Verhoef MJ, Scott CM, Hilsden RJ: A multimethod research study on the use of complementary therapies among patients with inflammatory bowel disease. Altern Ther Health Med 1998;4:68–71.
5.
Xinnong C: Chinese Acupuncture and Moxibustion, ed 2. Beijing, Foreign Languages Press, 1990.
6.
Macioca G: The Practice of Chinese Medicine, ed 1. New York, Churchill Livingstone, 1994.
7.
Gendo U: Ulcerative Colitis and Crohn’s disease in traditional Chinese medicine. Naturamed 1996;11:32–38.
8.
Zhang X: 23 Cases of chronic nonspecific ulcerative colitis treated by acupuncture and moxibustion. J Trad Chin Med 1998;18:188–191.
9.
Chen Z: Treatment of ulcerative colitis with acupuncture. J Trad Chin Med 1995;15:231–233.
10.
Best WR, Becktel JM, Singleton JW: Rederived values of the Crohn’s disease activity index (CDAI). Gastroenterology 1979;77:843–846.
11.
Summers RW, Switz DM, Sessions J et al: National cooperative Crohn’s disease study (ECCDS): Results of drug treatment. Gastroenterology 1979;77:847–869.
12.
Greenberg GR, Feagan BG, Martin F, et al: Oral budenoside as maintenance treatment for Crohn’s disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996;110:45–51.
13.
Irvine EJ, Feagan B, Rochon J, et al: Quality of life. A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287–296.
14.
Borkovec TD, Nau SD: Credibility of analogue therapy rationales. J Behav Ther Exp Psychiatry 1972,3:257–260.
15.
Vincent C, Lewith G: Placebo controls for acupuncture studies. J R Soc Med 1995;88:199–202.
16.
Cohen J: Statistical Power Analysis for the Behavioral Sciences. New York, Academic Press, 1988.
17.
Schouten HJA: Adaptive biased urn randomization in small strata when blinding is impossible. Biometrics 1995;51:1529–1535.
18.
Vincent CA, Richardson PH: The evaluation of therapeutic acupuncture: Concepts and methods. Pain 1986;24:1–13.
19.
Streitberger K, Kleinhenz J: Introducing a placebo needle into acupuncture research. Lancet 1998;352:364–365.
20.
Chaput de Saintonge DM, Herxheimer A: Harnessing placebo effects in health care. Lancet 1994;344:995–998.
21.
Vallis TM, Turnbull GK: Impact of disease activity on the quality of life of Crohn’s disease patients. Can J Gastroenterol 1996;10:310–315.
22.
Joos S, Schott C, Zou H, et al: Immunologic effects of acupuncture in the treatment of allergic asthma. J Altern Complement Med 2000;6:519–525.
23.
Li J, Jiang L, Hu G, et al: The influence of acupuncture on different lymphocyte subgroups. Chin Acup Moxib 1991;2:39–42.
24.
Lundeberg T, Eriksson SV, Theodorsson E: Neuroimmunomodulatory effects of acupuncture in mice. Neurosci Lett 1991;128:161–164.
25.
Dawidson I, Angmar-Mansson B, Blom M, et al: The influence of sensory stimulation (acupuncture) on the release of neuropeptides in the saliva of healthy subjects. Life Sci 1998;63:659–674.
26.
Jin HO, Zhou L, Lee KY, et al: Inhibition of acid secretion by electrical acupuncture is mediated via β-endorphine and somatostatin. Am J Physiol 1996;271:524–530.
27.
Anton PA, Shanahan F: Neuroimmunomodulation in inflammatory bowel disease. How far from ‘bench’ to ‘bedside’? Ann NY Acad Sci 1998;840:723–734.
28.
Ottaway CA: Role of the neuroendocrine system in cytokine pathways in inflammatory bowel disease. Aliment Pharmacol Ther 1996;10:10–15.
29.
Stack WA, Mann SD, Heath P, et al: Randomized controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn’s disease. Lancet 1997;349:512–524.
30.
Slonim AE, Bulone L, Damore MB, et al: A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med 2000;342:1633–1637.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.